The antibody discovery team of Zhihe Biotechnology (Beijing) Co., Ltd. originated from the Chinese Academy of Sciences. It has continuously undertaken the national "863" program antibody engineering tasks for 25 years and is a pioneer and founder of the field of genetically engineered antibodies in China.
Zhihe Xinchuang has a complete full-species antibody discovery technology system, covering all key aspects of target preparation, antibody screening, antibody optimization and antibody evaluation. Integrate hybridoma, phage antibody library and single B cell technology to provide comprehensive and meticulous solutions for the needs of antibody screening and optimization of different species.
Zhihe Tongchuang has three core technologies:
(1) Pharmaceutical-grade electrofusion hybridoma technology;
(2) Technology to rapidly construct tens of billions of ultra-large antibody libraries;
(3) High-throughput/all-species antibody molecule conversion technology.
Zhihe Innovation provides high-quality antibody discovery technology services to domestic and foreign antibody drug companies, cell therapy companies, in vitro diagnostic companies, scientific research institutes and universities. In the future, we will continue to uphold scientific concepts, empower the global antibody industry, build a "practical" antibody discovery technology platform with ingenuity, and develop "truly useful" antibody products for customers.
中文